Status:
COMPLETED
Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines
Lead Sponsor:
AstraZeneca
Conditions:
Covid-19
Eligibility:
All Genders
16+ years
Brief Summary
Background/Rationale: A very rare syndrome of thrombosis associated with low platelets has been reported in a few cases of recent exposure to COVID-19 vaccine. This thrombotic thrombocytopenia syndrom...
Eligibility Criteria
Inclusion
- A minimum of 12 months medical history prior to the start of the study period
Exclusion
- Less than 12 moths medical history prior to the start of the study period
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 11 2023
Estimated Enrollment :
7641136 Patients enrolled
Trial Details
Trial ID
NCT05252442
Start Date
March 1 2022
End Date
July 11 2023
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research site
Oxford, United Kingdom, OX12JD